Literature DB >> 24752277

The low keratin affinity of efinaconazole contributes to its nail penetration and fungicidal activity in topical onychomycosis treatment.

Keita Sugiura1, Noriaki Sugimoto2, Shinya Hosaka2, Maria Katafuchi-Nagashima3, Yoshio Arakawa3, Yoshiyuki Tatsumi3, William Jo Siu4, Radhakrishnan Pillai4.   

Abstract

Onychomycosis is a common fungal nail disease that is difficult to treat topically due to the deep location of the infection under the densely keratinized nail plate. Keratin affinity of topical drugs is an important physicochemical property impacting therapeutic efficacy. To be effective, topical drugs must penetrate the nail bed and retain their antifungal activity within the nail matrix, both of which are adversely affected by keratin binding. We investigated these properties for efinaconazole, a new topical antifungal for onychomycosis, compared with those of the existing topical drugs ciclopirox and amorolfine. The efinaconazole free-drug concentration in keratin suspensions was 14.3%, significantly higher than the concentrations of ciclopirox and amorolfine, which were 0.7% and 1.9%, respectively (P < 0.001). Efinaconazole was released from keratin at a higher proportion than in the reference drugs, with about half of the remaining keratin-bound efinaconazole removed after washing. In single-dose in vitro studies, efinaconazole penetrated full-thickness human nails into the receptor phase and also inhibited the growth of Trichophyton rubrum under the nail. In the presence of keratin, efinaconazole exhibited fungicidal activity against Trichophyton mentagrophytes comparable to that of amorolfine and superior to that of ciclopirox. In a guinea pig onychomycosis model with T. mentagrophytes infection, an efinaconazole solution significantly decreased nail fungal burden compared to that of ciclopirox and amorolfine lacquers (P < 0.01). These results suggest that the high nail permeability of efinaconazole and its potent fungicidal activity in the presence of keratin are related to its low keratin affinity, which may contribute to its efficacy in onychomycosis.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24752277      PMCID: PMC4068573          DOI: 10.1128/AAC.00111-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Enhanced human nail drug delivery: nail inner drug content assayed by new unique method.

Authors:  Xiaoying Hui; Zev Shainhouse; Hanafi Tanojo; Angela Anigbogu; George E Markus; Howard I Maibach; Ronald C Wester
Journal:  J Pharm Sci       Date:  2002-01       Impact factor: 3.534

Review 2.  Drug delivery to the nail following topical application.

Authors:  Sudaxshina Murdan
Journal:  Int J Pharm       Date:  2002-04-02       Impact factor: 5.875

3.  In vitro antifungal activity of KP-103, a novel triazole derivative, and its therapeutic efficacy against experimental plantar tinea pedis and cutaneous candidiasis in guinea pigs.

Authors:  Y Tatsumi; M Yokoo; T Arika; H Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

4.  Single-blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly.

Authors:  A K Gupta; N Konnikov; C W Lynde
Journal:  J Am Acad Dermatol       Date:  2001-03       Impact factor: 11.527

5.  Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild-to-moderate toenail onychomycosis: results from three randomized studies using double-blind vehicle-controlled and open-label active-controlled designs.

Authors:  B E Elewski; M A Ghannoum; P Mayser; A K Gupta; H-C Korting; R J Shouey; D R Baker; P A Rich; M Ling; S Hugot; B Damaj; J Nyirady; K Thangavelu; M Notter; A Parneix-Spake; B Sigurgeirsson
Journal:  J Eur Acad Dermatol Venereol       Date:  2011-12-20       Impact factor: 6.166

6.  Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis.

Authors:  A K Gupta; P Fleckman; R Baran
Journal:  J Am Acad Dermatol       Date:  2000-10       Impact factor: 11.527

7.  Therapeutic efficacy of topically applied KP-103 against experimental tinea unguium in guinea pigs in comparison with amorolfine and terbinafine.

Authors:  Yoshiyuki Tatsumi; Mamoru Yokoo; Hisato Senda; Kazuaki Kakehi
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

8.  A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns.

Authors:  M A Ghannoum; R A Hajjeh; R Scher; N Konnikov; A K Gupta; R Summerbell; S Sullivan; R Daniel; P Krusinski; P Fleckman; P Rich; R Odom; R Aly; D Pariser; M Zaiac; G Rebell; J Lesher; B Gerlach; G F Ponce-De-Leon; A Ghannoum; J Warner; N Isham; B Elewski
Journal:  J Am Acad Dermatol       Date:  2000-10       Impact factor: 11.527

Review 9.  Onychomycosis. Treatment, quality of life, and economic issues.

Authors:  B E Elewski
Journal:  Am J Clin Dermatol       Date:  2000 Jan-Feb       Impact factor: 7.403

10.  Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies.

Authors:  Boni E Elewski; Phoebe Rich; Richard Pollak; David M Pariser; Shinichi Watanabe; Hisato Senda; Chikara Ieda; Kathleen Smith; Radhakrishnan Pillai; Tage Ramakrishna; Jason T Olin
Journal:  J Am Acad Dermatol       Date:  2012-11-20       Impact factor: 11.527

View more
  16 in total

1.  In Vitro Human Onychopharmacokinetic and Pharmacodynamic Analyses of ME1111, a New Topical Agent for Onychomycosis.

Authors:  Natsuki Kubota-Ishida; Naomi Takei-Masuda; Kaori Kaneda; Yu Nagira; Tsubasa Chikada; Masahiro Nomoto; Yuji Tabata; Sho Takahata; Kazunori Maebashi; Xiaoying Hui; Howard I Maibach
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

Review 2.  Relevant Animal Models in Dermatophyte Research.

Authors:  Ludivine Cambier; Marie-Pierre Heinen; Bernard Mignon
Journal:  Mycopathologia       Date:  2016-10-11       Impact factor: 2.574

3.  In Vitro Antifungal Activity of Novel Triazole Efinaconazole and Five Comparators against Dermatophyte Isolates.

Authors:  Ali Rezaei-Matehkolaei; Sadegh Khodavaisy; Mohamad Mahdi Alshahni; Takashi Tamura; Kazuo Satoh; Mahdi Abastabar; Gholam Reza Shokoohi; Bahram Ahmadi; Mohammad Kord; Simin Taghipour; Koichi Makimura; Hamid Badali
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

4.  Evaluation of Topical Antifungals Using a New Predictive Animal Model for Efficacy against Severe Tinea Unguium: A Comparison of Efinaconazole and Luliconazole.

Authors:  Akane Masumoto; Keita Sugiura; Yoshiki Matsuda; Haruki Tachibana; Yoshiyuki Tatsumi
Journal:  Mycopathologia       Date:  2022-09-12       Impact factor: 3.785

5.  Characterization of Antifungal Activity and Nail Penetration of ME1111, a New Antifungal Agent for Topical Treatment of Onychomycosis.

Authors:  Yuji Tabata; Naomi Takei-Masuda; Natsuki Kubota; Sho Takahata; Makoto Ohyama; Kaori Kaneda; Maiko Iida; Kazunori Maebashi
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

Review 6.  Efinaconazole in the treatment of onychomycosis.

Authors:  Shari R Lipner; Richard K Scher
Journal:  Infect Drug Resist       Date:  2015-06-01       Impact factor: 4.003

Review 7.  Patient considerations in the management of toe onychomycosis - role of efinaconazole.

Authors:  Charlotte E LaSenna; Antonella Tosti
Journal:  Patient Prefer Adherence       Date:  2015-06-30       Impact factor: 2.711

8.  Efficacy Coefficients Determined Using Nail Permeability and Antifungal Activity in Keratin-Containing Media Are Useful for Predicting Clinical Efficacies of Topical Drugs for Onychomycosis.

Authors:  Yoshiki Matsuda; Keita Sugiura; Takashi Hashimoto; Akane Ueda; Yoshihiro Konno; Yoshiyuki Tatsumi
Journal:  PLoS One       Date:  2016-07-21       Impact factor: 3.240

9.  An Assessment of In Vitro Antifungal Activities of Efinaconazole and Itraconazole against Common Non-Dermatophyte Fungi Causing Onychomycosis.

Authors:  Ananya Tupaki-Sreepurna; Bhavna T Jishnu; Vijayakishore Thanneru; Savitri Sharma; Anjana Gopi; Murugan Sundaram; Anupma Jyoti Kindo
Journal:  J Fungi (Basel)       Date:  2017-05-05

10.  Fungicidal Activity in the Presence of Keratin as an Important Factor Contributing to In Vivo Efficacy: A Comparison of Efinaconazole, Tavaborole, and Ciclopirox.

Authors:  Haruki Tachibana; Naomichi Kumagai; Yoshiyuki Tatsumi
Journal:  J Fungi (Basel)       Date:  2017-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.